Firm announced a cooperative research agreement with U.K.-based Johnson Matthey under which Roberts will receive worldwide rights to all radiosensitizer drugs synthesized by Johnson Matthey for an undisclosed amount of cash. Compounds include organometallic hypoxic tumor cell radiosensitizers, oxic tumor cell radiosensitizers and targeted radiosensitizers.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.